Proactive Investors: “ReNeuron ‘very encouraged’ by positive retinitis pigmentosa study results”
Proactive Investors : “ReNeuron Group agrees £80mln cell therapy licensing deal for China”
Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Proactive Investors: ReNeuron seeing increased interest across its assets from potential licensee partners
Proactive Investors : “ReNeuron signs exosome collaboration deal with US biopharma”
OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Proactive Investors ‘ReNeuron focus on new clinical trials’
Proactive investors ‘Breakthrough to open up potential new revenue opportunities for Reneuron Plc’
Shares Investor Evening (Manchester) – October 2018